First patient dosed in phase 1b/2a trial of oral danegaptide for diabetic retinopathy

Breye Therapeutics has begun dosing in its phase 1b/2a trial of oral danegaptide for treatment of diabetic macular edema, according to a company press release.
“The launch of the phase 1b/2a clinical trial for danegaptide represents a significant milestone towards realizing our mission of developing more effective, globally accessible orally administered treatment solutions for patients at risk of vision loss and blindness,” Ulrik Mouritzen, MD, Breye’s CEO, said in the release. “The burden on patients with diabetic retinopathy is significant, and those who experience

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart